<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02300129</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR.40225E</org_study_id>
    <nct_id>NCT02300129</nct_id>
  </id_info>
  <brief_title>Effect of CD07805/47 Gel in Rosacea Flushing</brief_title>
  <official_title>Effect of CD07805/47 Gel in Subjects Presenting With Flushing Related to Erythematotelangiectatic or Papulopustular Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma R&amp;D</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2a study to assess the efficacy and safety of CD07805/47 0.5% gel in the prevention of&#xD;
      the flush of rosacea.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this study in rosacea patients (type I&amp;II) are:&#xD;
&#xD;
        -  to demonstrate objectively that CD07805/47 0.5% gel is able to prevent a flush induced&#xD;
           by a specific trigger (hot water) in controlled condition;&#xD;
&#xD;
        -  to demonstrate that CD07805/47 0.5% gel is able to prevent a flush whatever the trigger&#xD;
           in everyday life condition;&#xD;
&#xD;
        -  to investigate if reduction in redness is associated with a decrease in skin sensations&#xD;
           such as heat, stinging/burning, skin tension and sweating;&#xD;
&#xD;
        -  to demonstrate that such efficacy on transient redness and sensations takes place in&#xD;
           both populations (rosacea type I and rosacea type II).&#xD;
&#xD;
      This is a single-centre, randomized, Investigator masked, placebo controlled study comprising&#xD;
      the following periods:&#xD;
&#xD;
      A screening period of maximum 4 weeks&#xD;
&#xD;
      A one-week treatment phase (Period 1) with 3 sessions using the flush model, every other day.&#xD;
&#xD;
      This Period 1 includes a cross-over design (first and third sessions) and a split face design&#xD;
      (second session). During this period, thirty six (36) subjects will receive on site the study&#xD;
      drugs as follows (the order of each session being randomized):&#xD;
&#xD;
        -  CD07805/47 placebo gel on both sides of the face,&#xD;
&#xD;
        -  one side of the face treated with CD07805/47 0.5% gel, the other side treated with the&#xD;
           CD07805/47 placebo gel (the allocation of treatment on each half-face will be determined&#xD;
           according to a randomization list),&#xD;
&#xD;
        -  CD07805/47 0.5% gel on both sides of the face;&#xD;
&#xD;
      A 2-days wash-out period (between Period 1 and Period 2) with no treatment on either side of&#xD;
      the face&#xD;
&#xD;
      A 4-week treatment phase (Period 2) corresponding to a cross-over design during which the&#xD;
      subjects will apply themselves the study drugs at home on the whole face, once daily 7 days&#xD;
      per week.&#xD;
&#xD;
      The subjects will be divided in 2 groups of eighteen (18) subjects and will receive either&#xD;
      the CD07805/47 0.5% gel the first 2 weeks and then the CD07805/47 placebo gel or the&#xD;
      CD07805/47 placebo gel the first 2 weeks and then the CD07805/47 0.5% gel, according to&#xD;
      randomization.&#xD;
&#xD;
      All the subjects taking part into the study will not be randomized separately in the two&#xD;
      periods but to the full sequence at the beginning of the clinical trial (same randomization&#xD;
      number during all the study), explaining the arms/groups detailed in the section &quot;Arms and&#xD;
      Interventions&quot;.&#xD;
&#xD;
      Only primary efficacy endpoint: total number of flushes for each 2-week period will be&#xD;
      detailed in the outcome measures section.&#xD;
&#xD;
      The other endpoints are secondary or exploratory.&#xD;
&#xD;
      The purpose of Period 1 is to assess whether simpler and shorter designs based on flush&#xD;
      induced by a trigger could be as efficient to detect prevention of flush than the more&#xD;
      classical and longer design of Period 2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Number of Flushes for Each 2-week Period</measure>
    <time_frame>Day 22 and Day 36/Early termination</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1:&#xD;
Application of 1g of CD07805/47 0.5% Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.&#xD;
Application of 500mg of Placebo Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design)&#xD;
Period 2 (cross-over design):&#xD;
Application of 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks then 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1:&#xD;
Application of 1g of Placebo Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.&#xD;
Application of 500mg of CD07805/47 0.5% Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).&#xD;
Period 2 (cross-over design):&#xD;
Application of 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks then 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1:&#xD;
Application of 1g of CD07805/47 0.5% Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.&#xD;
Application of 500mg of Placebo Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).&#xD;
Period 2 (cross-over design):&#xD;
Application of 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks then 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1:&#xD;
Application of 1g of Placebo Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.&#xD;
Application of 500mg of CD07805/47 0.5% Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).&#xD;
Period 2 (cross-over design):&#xD;
Application of 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks then 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo</intervention_name>
    <description>Period 1:&#xD;
1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.&#xD;
500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.&#xD;
Period 2:&#xD;
1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.&#xD;
1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks.</description>
    <arm_group_label>CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo</intervention_name>
    <description>Period 1:&#xD;
1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.&#xD;
500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.&#xD;
Period 2:&#xD;
1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.&#xD;
1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks.</description>
    <arm_group_label>Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47</intervention_name>
    <description>Period 1:&#xD;
1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.&#xD;
500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.&#xD;
Period 2:&#xD;
1g of Placebo on full face once daily 7 days per week for 2 weeks.&#xD;
1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks.</description>
    <arm_group_label>CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47</intervention_name>
    <description>Period 1:&#xD;
1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.&#xD;
500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.&#xD;
Period 2:&#xD;
1g of Placebo on full face once daily 7 days per week for 2 weeks.&#xD;
1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks.</description>
    <arm_group_label>Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subject is a male or female, who is at least 18 years of age or older at Screening&#xD;
             visit.&#xD;
&#xD;
          2. The subject has a clinical diagnosis of mild to moderate erythemato-telangiectatic&#xD;
             rosacea or mild to moderate papulo-pustular rosacea according to the National Rosacea&#xD;
             Society grading (Wilkin et al., 2004)&#xD;
&#xD;
          3. The subject had at least five flushing episodes during the last week before Screening&#xD;
             and Baseline visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The subject has particular forms of rosacea (rosacea conglobata, rosacea fulminans,&#xD;
             isolated rhinophyma, isolated pustulosis of the chin), or other concomitant facial&#xD;
             dermatoses that are similar to rosacea such as peri-oral dermatitis, demodicidosis&#xD;
             facial keratosis pilaris, seborrheic dermatitis, acute lupus erythematosus or actinic&#xD;
             telangiectasia;&#xD;
&#xD;
          2. The subject has current treatment with monoamine oxidase inhibitors, barbiturates,&#xD;
             opiates, sedatives, systemic anesthetics, or alpha-agonists;&#xD;
&#xD;
          3. The subject has less than 3 months stable dose treatment with tricyclic&#xD;
             anti-depressants, cardiac glycosides, beta blockers or other antihypertensive agents;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Galderma Investigational site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>November 20, 2014</study_first_submitted>
  <study_first_submitted_qc>November 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2014</study_first_posted>
  <results_first_submitted>October 20, 2015</results_first_submitted>
  <results_first_submitted_qc>August 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 20, 2016</results_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
    <mesh_term>Flushing</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo</title>
          <description>Period 1:&#xD;
Application of 1g of CD07805/47 0.5% Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.&#xD;
Application of 500mg of Placebo Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).&#xD;
Period 2 (cross-over design):&#xD;
Application of 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks then 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo</title>
          <description>Period 1:&#xD;
Application of 1g of Placebo Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.&#xD;
Application of 500mg of CD07805/47 0.5% Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).&#xD;
Period 2 (cross-over design):&#xD;
Application of 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks then 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks.</description>
        </group>
        <group group_id="P3">
          <title>CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47</title>
          <description>Period 1:&#xD;
Application of 1g of CD07805/47 0.5% Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.&#xD;
Application of 500mg of Placebo Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).&#xD;
Period 2 (cross-over design):&#xD;
Application of 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks then 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47</title>
          <description>Period 1:&#xD;
Application of 1g of Placebo Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.&#xD;
Application of 500mg of CD07805/47 0.5% Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).&#xD;
Period 2 (cross-over design):&#xD;
Application of 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks then 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 Session 1 (Day 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 1 Session 2 (Day 3)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5">Withdrawal consent of 1 subject between Day 1 and Day 3</participants>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 1 Session 3 (Day 5)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2 Treatment 1 (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="11">Withdrawal consent of 1 subject between the Period 1 and Period 2</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2 Treatment 2 (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to Treat population</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants (Intent To Treat Population)</title>
          <description>One subject was excluded from Intent to Treat (ITT) population because he didn't perform any efficacy assessment during the study so N=33 instead of 34 subjects</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.2" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Number of Flushes for Each 2-week Period</title>
        <time_frame>Day 22 and Day 36/Early termination</time_frame>
        <population>Per protocol population of Period 2, N= 31</population>
        <group_list>
          <group group_id="O1">
            <title>Period 2 CD07805/47 0.5% Gel Cross-over</title>
            <description>CD07805/47 0.5% gel (Brimonidine tartrate)</description>
          </group>
          <group group_id="O2">
            <title>Period 2 Placebo Gel Cross-over</title>
            <description>CD07805/47 placebo gel</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Flushes for Each 2-week Period</title>
          <population>Per protocol population of Period 2, N= 31</population>
          <units>Flushes count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" spread="12.1"/>
                    <measurement group_id="O2" value="16.3" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7420</p_value>
            <p_value_desc>P value associated to treatment effect in the model. Study design with a power of 80% and a type I error at 5% (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Analysis of variance including sequence, subject (sequence), period and treatment as factors in the model</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Period 1 Placebo Gel Cross Over</title>
          <description>Period 1 Placebo gel cross over (application on full face) Overall safety population, N=34</description>
        </group>
        <group group_id="E2">
          <title>Period 1 CD07805/47 0.5% Gel Split Face</title>
          <description>Period 1 CD07805/47 0.5% gel split face (application on one side of face) Overall safety population, N=33</description>
        </group>
        <group group_id="E3">
          <title>Period 1 Placebo Gel Split Face</title>
          <description>Period 1 Placebo gel split face (application on one side of face) Overall safety population, N=33</description>
        </group>
        <group group_id="E4">
          <title>Period 1 CD07805/47 0.5% Gel Cross-over</title>
          <description>Period 1 CD07805/47 0.5% cross over (application on full face) Overall safety population, N=33</description>
        </group>
        <group group_id="E5">
          <title>Period 2 CD07805/47 0.5% Gel Cross Over</title>
          <description>Period 2 CD07805/47 0.5% gel (application on full face) Overall safety population, N=32</description>
        </group>
        <group group_id="E6">
          <title>Period 2 Placebo Gel Cross Over</title>
          <description>Period 2 Placebo gel cross over (application on full face) Overall safety population, N=31</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema of eyelid</sub_title>
                <description>Cutaneous AE not related to CD07805/47 0.5 gel</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cheilitis</sub_title>
                <description>Cutaneous AE not related to CD07805/47 0.5 gel</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral herpes</sub_title>
                <description>Cutaneous AE not related to CD07805/47 0.5 gel</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <description>Non cutaneous AE</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Non cutaneous AE</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema and skin tightness</sub_title>
                <description>Cutaneous AE related to CD07805/47 0.5% gel</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Erythema, papules and pruritus</sub_title>
                <description>Cutaneous AE related to CD07805/47 placebo gel</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="6" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Erythema, papules and pruritus</sub_title>
                <description>AE of Special Interest related to CD07805/47 0.5% gel leading to subject discontinuation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Galderma CPM</name_or_title>
      <organization>Galderma R&amp;D</organization>
      <phone>00 33 4 93 95 70 70</phone>
      <email>clinicaltrials@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

